Director/PDMR Shareholding

RNS Number : 6189J
Immupharma PLC
24 August 2021
 

 

24 August 2021

ImmuPharma PLC

("ImmuPharma" or the "Company")

Director & PDMR Share Purchases

 

ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that each member of the Board of Directors and PDMR, Ewa Flynn (Chief Financial Officer) have on 23 & 24 August 2021 purchased in total 670,000 ordinary shares of 10p in the Company ("Ordinary Shares").

 

 

Details of the share purchases by the Board and their current interests in shares following the transactions are set out below.

 

NAME & TITLE

ORDINARY SHARES PURCHASED

& PURCHASE PRICE

NUMBER OF ORDINARY SHARES HELD POST TRANSACTION

% OF ISSUED SHARE CAPITAL

Tim McCarthy

Chairman & Chief Executive Officer

250,000 @ 8.26p

288,462

0.12%

Dr Tim Franklin

Chief Operating Officer

125,000 @ 7.99p

125,000

0.05%

Dr Sanjeev Pandya

Senior Non-Executive Director

125,000 @ 8.00p

125,000

 

0.05%

Lisa Baderoon

Non-Executive Director & Head of Investor Relations

140,000 @ 8.1957p

183,963

0.07%

Ewa Flynn

Chief Financial Officer &

Company Secretary

30,000 @ 7.892p

30,000

0.01%

 

 

Full disclosure of the transactions by persons discharging managerial responsibilities and persons closely associated with them ("PDMR's") are detailed at the end of the announcement.

End

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended.  on publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 

 

 

 

 

For further information please contact:

 

ImmuPharma PLC ( www.immupharma.com )

Tim McCarthy, Chairman and Chief Executive Officer

+ 44 (0) 207 152 4080

Dr Tim Franklin, Chief Operating Officer

 

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge

John Howes

Bob Pountney

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0) 203 36 8 3550

 

 

+44 (0) 203 815 8880

 

 

 

 

+44 (0) 1483 413500

 

 

4Reliance (Euronext Growth Listing Sponsor)

Jean-Charles Snoy

 

Degroof Petercam (Liquidity Provider)

Erik De Clippel

 

Backstage Communication

Olivier Duquaine

Gunther De Backer

+32 (0) 2 747 02 60

 

 

+32 (0) 2 287 95 34

 

 

 

+32 (0) 477 504 784

+32 (0) 475 903 909

 

 

 

 

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 3 trial for Lupuzor™ and commercialise in the US.

For additional information about ImmuPharma please visit www.immupharma.co.uk  

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

Name

Tim McCarthy

2

Reason for the notification

a)

Position / status

Chairman and Chief Executive Officer

b)

Initial notification / Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

ImmuPharma PLC

b)

LEI

213800VZKGHXC7VUS895

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument , type of instrument

 

Identification code

 

Ordinary Shares of 10p each

 

 

ISIN: GB0033711010

b)

Nature of the transaction

On-market purchase

c)

 

Price(s) and volume(s)

 

Price

Volume

8.26p

250,000

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

e)

Date of the transaction

23 August 2021

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

Name

Dr Tim Franklin

2

Reason for the notification

a)

Position / status

Chief Operating Officer

b)

Initial notification / Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

ImmuPharma PLC

b)

LEI

213800VZKGHXC7VUS895

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument , type of instrument

 

Identification code

 

Ordinary Shares of 10p each

 

 

ISIN: GB0033711010

b)

Nature of the transaction

On-market purchase

c)

 

Price(s) and volume(s)

 

Price

Volume

7.99p

125,000

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

e)

Date of the transaction

24 August 2021

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

Name

Dr Sanjeev Pandya

2

Reason for the notification

a)

Position / status

Senior Non-Executive Director 

b)

Initial notification / Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

ImmuPharma PLC

b)

LEI

213800VZKGHXC7VUS895

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument , type of instrument

 

Identification code

 

Ordinary Shares of 10p each

 

 

ISIN: GB0033711010

b)

Nature of the transaction

On-market purchase

c)

 

Price(s) and volume(s)

 

Price

Volume

8p

125,000

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

e)

Date of the transaction

23 August 2021

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

Name

Lisa Baderoon

2

Reason for the notification

a)

Position / status

Non-Executive Director & Head of Investor Relations

b)

Initial notification / Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

ImmuPharma PLC

b)

LEI

213800VZKGHXC7VUS895

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument , type of instrument

 

Identification code

 

Ordinary Shares of 10p each

 

 

ISIN: GB0033711010

b)

Nature of the transaction

On-market purchase

c)

 

Price(s) and volume(s)

 

Price

Volume

8.1957p

140,000

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

e)

Date of the transaction

23 August 2021

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

Name

Ewa Flynn

2

Reason for the notification

a)

Position / status

Chief Financial Officer (PDMR)

b)

Initial notification / Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

ImmuPharma PLC

b)

LEI

213800VZKGHXC7VUS895

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument , type of instrument

 

Identification code

 

Ordinary Shares of 10p each

 

 

ISIN: GB0033711010

b)

Nature of the transaction

On-market purchase

c)

 

Price(s) and volume(s)

 

Price

Volume

7.892p

30,000

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

e)

Date of the transaction

23 August 2021

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHPIMMTMTMTBAB

Companies

Immupharma (IMM)
UK 100

Latest directors dealings